Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results.
Twelve patients with mycotic infections were treated with itraconazole during a one-year period. Patients had the following conditions: coccidioidomycosis (three), histoplasmosis (three), mucocutaneous candidosis (two), aspergillosis (three), and urinary tract infection due to Torulopsis glabrata (one). The daily dose of itraconazole ranged from 100 to 200 mg. Ten of the 12 cases were assessable. Clinical improvement was observed in six patients, two with coccidioidomycosis, two with mucocutaneous candidosis, one with histoplasmosis, and one with aspergilloma. Four patients did not respond to therapy; two of these patients had aspergillosis, one had histoplasmosis, and one had T. glabrata infection. No adverse effects were attributable to itraconazole.
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy; D002675:Child, Preschool; D003047:Coccidioidomycosis / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy
D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole